EXEL News and Press, Exelixis Inc. From 08/24/23

2023-08-24 03:43:27 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis lead product hits main goal in Phase 3 prostate cancer trial For further details...

-- Dr. Peterson’s extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice ...

2023-08-22 09:28:26 ET More on Lilly Eli Lilly Q2: Dividends Don't Lie Eli Lilly: Q2 And 2023 Revised Guidance Impressive, But Key Is Wegovy Data Eli Lilly and Co ( LLY ) Q2 2023 Earnings Call Transcript Eli Lilly Remains A Buy With Strong Sales And Possi...

2023-08-21 07:29:59 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis, Teva settle patent dispute over cancer drug Cabometyx Exelixis a new overweight...

– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer – – A trend to...

2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...

2023-08-03 11:46:22 ET Summary Fitch Ratings threw a curveball at investors by downgrading its rating on U.S. federal debt for the first time since 2011 and only the second time ever. This triggered the largest one day sell-off in the NASDAQ since February and also saw volatility ...

2023-08-02 00:00:37 ET Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q2 2023 Earnings Call Aug 01, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q2 2023 Earnings Call Transcript

2023-08-01 22:20:21 ET Exelixis, Inc. (EXEL) Q2 2023 Earnings Conference Call August 01, 2023, 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer ...

2023-08-01 16:11:41 ET Exelixis press release ( NASDAQ: EXEL ): Q2 Non-GAAP EPS of $0.31 beats by $0.09 . Revenue of $469.85M (+12.0% Y/Y) beats by $25.02M . 2023 Outlook: Total revenues $1.775 billion - $1.875 billion; Net product revenues $1.575 billion -...